Obesity has been declared a disease by WHO. It is associated not only with heart disease, diabetes, stroke, gallstones, ...

The current pain caused by the high cost of the GLP-1 agonist anti-obesity drugs will pass. Prachi Patkee and other analysts ...

The global weight loss and obesity management market is set to experience remarkable expansion in the coming decade. With new ...

Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist development candidate expected ... as a potential best-in-class oral small molecule ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

The blockbuster drugs Ozempic and Wegovy may help people cut back on drinking, new research published Wednesday in JAMA ...

Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...

Scientists from the University of Copenhagen say they have developed a drug that decreases appetite while increasing calorie ...